In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Viewray (VRAY), with a price target of $20. The company’s shares opened today at $6.02, close to its 52-week low of $4.86.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 8.2% and a 53.7% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.
Viewray has an analyst consensus of Strong Buy, with a price target consensus of $13.11, representing an 117.8% upside. In a report issued on December 20, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.21 and a one-year low of $4.86. Currently, Viewray has an average volume of 1.4M.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRAY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
